Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633043 | 0.93 | ALK (0.44) | ALKTSHRALDH1A1PTK2PTK2B | |
| SCHEMBL4355241 | 0.90 | ALK (0.53) | ALKTSHRALDH1A1JAK2KDM4E | |
| SCHEMBL13634074 | 0.88 | ALK (0.41) | ALKPTK2PTK2BJAK2MEN1 | |
| SCHEMBL13633116 | 0.88 | MEN1 (0.48) | ALKMEN1KMT2ATRPV1HTT | |
| SCHEMBL13633048 | 0.87 | ALK (0.45) | ALKALDH1A1JAK2KDM4EMEN1 | |
| SCHEMBL13633117 | 0.86 | ALK (0.48) | ALKJAK2 | |
| SCHEMBL13633019 | 0.86 | ALK (0.44) | ALKALDH1A1JAK2MEN1KMT2A | |
| SCHEMBL13634077 | 0.85 | ALK (0.46) | ALKJAK2 | |
| SCHEMBL13632896 | 0.85 | ALK (0.44) | ALKJAK2MEN1KMT2A | |
| SCHEMBL13633050 | 0.85 | ALK (0.41) | ALKTSHRALDH1A1JAK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885TSHR 1918/4885ALDH1A1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.